Aller au contenu

514 606-3350

info@cliniqueomicron.ca​

FR / EN
Logo - Clinique Omicron
Make an appointment
Healthcare-Associated Infections: Prevention, Agents, and Management | Clinique Omicron
Infectious Diseases & Infection Prevention and Control & Critical Care & Internal Medicine

Nosocomial infections (healthcare-associated infections)

Get advice tailored to your situation

In-person or telemedicine consultations, anywhere in Quebec.

Healthcare-associated infections, now referred to as healthcare-associated infections (HAIs) to include infections occurring in any healthcare setting, including home care and long-term care, are defined by the CDC as infections that occur more than 48 hours after admission to a healthcare facility and were neither present nor incubating at the time of admission. They represent a major public health problem: in the United States, 1.7 million HAIs occur annually, resulting in 99,000 attributable deaths (Klevens 2007, Public Health Reports). In Canada, data from the PHAC (Public Health Agency of Canada) estimate the number of HAIs annually at 220,000 and the number of deaths directly attributable to them at 8,500. The four most common types are ventilator-associated pneumonia (VAP), central line-associated bloodstream infections (CLABSI), catheter-associated urinary tract infections (CAUTI), and surgical site infections (SSI). In addition to these classic HAIs is Clostridioides difficile infection (CDI), the leading cause of nosocomial diarrhea in developed countries. The most dangerous pathogens are multidrug-resistant bacteria (MDRB): MRSA (methicillin-resistant Staphylococcus aureus), VRE (vancomycin-resistant enterococci), enterobacteria producing ESBL or carbapenemases (EPC), and multidrug-resistant Acinetobacter baumannii. The prevention of healthcare-associated infections (HAIs) relies on essential measures: hand hygiene, contact/droplet/airborne precautions, structured care bundles for each type of HAI, prudent antibiotic use (antimicrobial stewardship), and active epidemiological surveillance.

Epidemiology, Causative Agents, and Mechanisms of Resistance

  • Epidemiology of Healthcare-Associated Infections and Major Nosocomial Pathogens: global and Canadian epidemiological data: overall prevalence of HCAIs in Canadian hospitals: 10-15 % of hospitalized patients have at least one HCAI → Klevens 2007 - Public Health Reports: 1.7 million HCAIs/year in the USA + 99,000 deaths → PHAC 2020: 220,000 HCAIs/year in Canada → ECDC Cassini 2019 - Lancet Infectious Diseases: European meta-analysis → 3.2 million HAIs/year in EU countries + 37,000 directly attributable deaths → HAIs are preventable in 30-70 % of cases (depending on type); distribution by type of HAI: healthcare-associated urinary tract infections (CAUTI): 35-40 % of HCAIs → main risk factor: urinary catheter → healthcare-associated pneumonia (HAP + VAP): 15-25 % + CVC bacteremia (CLABSI): 10-15 % + surgical site infections (SSI): 15-25 % + C. difficile (ICD): 10-15 % → clearly increasing since 2000s → main nosocomial pathogens (CDC NHSN data 2021): E. coli (CAUTI + ISO) + S. aureus (MRSA + MSSA) (ISO + VAP + CLABSI) + coagulase-negative Staphylococcus (CLABSI on CVC) + Enterococcus spp. (VRE) (CAUTI + CLABSI) + Klebsiella pneumoniae (ESBL + KPC) (VAP + CLABSI + CAUTI) + Pseudomonas aeruginosa (VAP + ISO) + Acinetobacter baumannii (VAP + CLABSI → hospitals in tropical areas + intensive care) + C. difficile (ICD); antibiotic resistance mechanisms - BMR: MRSA (resistance to meticillin via mecA gene → PBP2a protein → reduced affinity for beta-lactams → resistance to all beta-lactams) + treatment: vancomycin + daptomycin + linezolid + ceftaroline → VRE (vancomycin-resistant Enterococcus - vanA + vanB genes → modification of peptidoglycan precursor D-Ala-D-Lac instead of D-Ala-D-Ala → vancomycin no longer binds) + treatment: linezolid + daptomycin + quinupristin-dalfopristin (VanA only) + carbapenemase-producing enterobacteria (EPC - KPC + NDM + OXA-48 + VIM + IMP) → carbapenem resistance → very limited options: ceftazidime-avibactam + meropenem-vaborbactam + imipenem-cilastatin-relebactam + colistin (nephrotoxic) + multidrug-resistant Acinetobacter baumannii (MDR-AB) : resistance to almost all antibiotics → colistin + tigecycline → often pan-resistant in some regions → surveillance data Quebec: MSSS + INSPQ publish annual surveillance data on MRSA + VRE + C. difficile by healthcare facility in Quebec
  • Hand Hygiene and Standard Precautions : Fundamental Preventive Measures: hand hygiene - the most effective and least costly preventive measure: WHO (2009) - My 5 Moments for Hand Hygiene: 5 key indications: before touching the patient + before an aseptic procedure + after a risk of exposure to a biological fluid + after touching the patient + after touching the patient's environment → hydroalcoholic friction (FHA) : ethanol-based hydroalcoholic solution (SHA) (62-80 %) → 20-30 seconds + bactericidal efficacy superior to handwashing with soap and water unless hands visibly soiled + or C. difficile (sporulation - SHA ineffective → washing with soap and water mandatory) → Pittet 2000 - Lancet: improved hand hygiene compliance → 50 % reduction in HAIs → Génève → HH-Success program → Pittet 2001 - Annals of Internal Medicine: hand hygiene improvement program → MRSA reduction of 32 % → target compliance: ≥80 % in intensive care units + standard precautions: applicable to all patients systematically → blood + secretions + biological fluids → gloves + mask + goggles if projection risk → additional precautions protocols: contact (MRSA + VRE + C. difficile + Norovirus + RSV): room only + apron + gloves → droplets (influenza + COVID-19 + meningococcal meningitis + mumps + influenza): surgical mask + gloves → airborne (tuberculosis + chickenpox + measles + aerosol-generating SARS-CoV-2): negative pressure chamber + N95/FFP2 mask + gloves + gown → Cohen 2006 - SHEA/IDSA Practice Recommendations: additional precautions in HAIs → Siegel 2007 - CDC/HICPAC Guidelines: isolation precautions → international reference + MSSS Quebec + INSPQ: provincial infection prevention and control (IPC) protocols → regular updates

Specific IAS, Prevention and Treatment

IAS TypePrevention, Diagnosis, and TreatmentKey studies and recommendations
Clostridioides difficile infection (CDI)
C. difficile, oral vancomycin, fidaxomicin, bezlotoxumab, fecal transplant, recurrence, contact precautions, hypochlorite
Clostridioides difficile, epidemiology and pathogenesis: a spore-forming, Gram-positive, anaerobic bacterium → spores resistant to alcohol, heat, and most disinfectants → only chlorine (sodium hypochlorite, diluted bleach) destroys them + antibiotics → dysbiosis of the gut microbiota → C. difficile spores germinate → colonization + production of toxins A (enterotoxin) and B (cytotoxin) → pseudomembranous colitis → watery diarrhea + fever + abdominal pain → hypervirulent strain BI/NAP1/027: produces a binary toxin + hyperproduces toxins A and B + resistant to fluoroquinolones → outbreaks in North America since 2001 → risk factors for C. difficile infection (CDI): recent antibiotic use (especially clindamycin, quinolones, cephalosporins, and broad-spectrum penicillins) + prolonged hospital stays + PPIs + age >65 years + immunosuppression + gastrointestinal surgery; diagnosis of CDI: criteria: ≥3 loose stools/24 hours + EIA (Enzyme Immunoassay) for toxins A/B: rapid + specific (95 %) + but sensitivity 70–75 % → PCR (NAAT) on stool: sensitivity 90–97 % + specificity 97 % → detects asymptomatic carriers → risk of overdiagnosis → optimal algorithm: glutamate dehydrogenase (GDH : C. difficile antigen) for screening → if positive → toxin EIA → if negative → PCR (2- or 3-step algorithm) → Crobach 2016, Clinical Microbiology and Infection (meta-analysis): GDH + EIA + PCR algorithm → better performance + avoids overdiagnosis; Treatment of C. difficile infection (CDI): initial non-severe episode: fidaxomicin (Dificid) 200 mg twice daily for 10 days → superior to oral vancomycin in reducing recurrences → Louie 2011, NEJM (RCT): fidaxomicin vs. vancomycin → similar cure rates + recurrence rates: 15 % vs. 25 % → recommended as first-line therapy (IDSA 2021 + SHEA 2022) + or oral vancomycin 125 mg × 4/day × 10 days → less expensive alternative → severe initial episode (leukocytosis >15 × 10⁹/L or creatinine >1.5 × normal or albumin antibiotics for recurrent CDI → Van Nood 2013, NEJM: FMT via nasoduodenal tube → 81 % vs. 31 % vancomycin → trial halted → FMT = standard of care for multiple recurrent CDI + Ribaxamase and SYN-004: enzymes that break down antibiotics in the gastrointestinal tract → reduction in dysbiosis → clinical trials; specific precautions for C. difficile: strict contact precautions + single room + handwashing with soap and water (hand sanitizer is ineffective against spores) + wearing gloves and a gown → surface disinfection with sodium hypochlorite 1000–5000 ppm (bleach diluted 1:10) → maintain precautions for up to 48–72 hours after symptoms resolve → no treatment for asymptomatic carriers → INSPQ + MSSS Quebec: protocols for controlling C. difficile outbreaks Louie 2011 : NEJM (RCT): fidaxomicin vs. vancomycin → similar cure rates + recurrence rates of 15 % vs. 25 % → fidaxomicin superior + Wilcox 2017, NEJM (MODIFY I + II trials): bezlotoxumab → 40% reduction in relapses at % → indicated if FdR + Van Nood 2013, NEJM: TMF vs. vancomycin → 81 % vs. 31 % → trial halted + Paramsothy 2017, Lancet: TMF > antibiotics for recurrent ICDs → Crobach 2016, CMI: GDH + EIA + PCR algorithm → better diagnostic performance → + McDonald 2018, Clinical Infectious Diseases (IDSA/SHEA Guidelines): C. difficile treatment 2018 → vancomycin + fidaxomicin as first-line therapy → metronidazole no longer recommended as first-line therapy + Kelly 2021, IDSA/SHEA 2021 update: fidaxomicin = first-line treatment + bezlotoxumab if C. difficile recurs + INSPQ Quebec: C. difficile control protocols in healthcare facilities → mandatory epidemiological surveillance + reporting to the MSSS
Ventilator-Associated Pneumonia (VAP) and Hospital-Acquired Pneumonia (HAP)
CDC Definition : Criteria : VAP Prevention Bundle, Head of the bed at 30–45°, Oral Hygiene, Cuff Pressure, VAP Antibiotic Therapy, Cultures, De-escalation
VAP, definition and epidemiology: pneumonia occurring ≥48 hours after endotracheal intubation → incidence: 10–25 % of patients on mechanical ventilation → attributable mortality: 10–25 % → prolongs the duration of mechanical ventilation by 7–9 days and the length of stay in the ICU by 5–7 days → high cost → pathogens: early-onset (<5 days): S. aureus + H. influenzae + S. pneumoniae + susceptible Enterobacteriaceae → late-onset (≥5 days): P. aeruginosa + MRSA S. aureus + ESBL/KPC Klebsiella + Acinetobacter → mechanism: microinhalation of colonized oropharyngeal secretions around the intubation tube cuff → biofilm on the tube → VAP bundle (ventilator bundle), prevention: head of the bed elevated to 30–45° (unless contraindicated, reduces microinhalation) + oral hygiene with 0.12% chlorhexidine % × 2–4 times perday + monitoring of endotracheal tube cuff pressure (20–30 cmH₂O) → insufficient pressure → microinhalations + excessive pressure → tracheal necrosis + daily interruption of sedation + assessment ofextubation → reduce duration of mechanical ventilation + prefer nasogastric tube over tube feeding if enteral feeding is required → prefer semi-sitting position + continuous subglottic suction (endotracheal tube with suction channel) → Coffin 2008, Infection Control and Hospital Epidemiology: VAP bundle → 50–70% reduction in incidence + CDC / Institute for Healthcare Improvement (IHI): VAP bundle → standard recommendation + Institute for Safe Medication Practices (ISMP) + Pronovost 2006, NEJM: Keystone Project : Michigan → application of the CVC bundle → 66% reduction in CLABSI → applicable to the VAP bundle; VAP diagnosis: clinical + radiological + microbiological criteria → fever + leukocytosis + purulent secretions + radiographic infiltrates → but: low specificity → cultures: bronchoalveolar lavage (BAL) + tracheal aspirate → quantitative if possible (threshold: BAL ≥10⁴ CFU/mL + tracheal aspirate ≥10⁵ CFU/mL) + semi-quantitative culture + direct Gram stain → biomarkers: procalcitonin + CRP → guide treatment duration + treatment of VAP: empirical antibiotic therapy based on the risk of multidrug-resistant organisms and local data: early-onset VAP (≤5 days) without risk factors for resistance: cefazolin 1 g × 3/day IV → or amoxicillin-clavulanate 1.2 g × 3/day IV → or ceftriaxone 2 g/day IV → late VAP (≥5 days) or risk factors for resistance (recent antibiotic therapy + prolonged hospitalization + prolonged mechanical ventilation + previously documented MRSA or Pseudomonas): piperacillin-tazobactam 4.5 g × 4/day IV + and/or meropenem 1–2 g × 3/day IV + MRSA: IV vancomycin + or linezolid → de-escalation as soon as culture results are available → duration: generally 7–8 days (Chastre 2003 : JAMA: 8 days = 15 days for VAP except for Pseudomonas + Acinetobacter → shorter course recommended) Coffin 2008 : Infection Control and Hospital Epidemiology: VAP bundle → 50–70% reduction in % incidence + Pronovost 2006, NEJM (Keystone Michigan): implementation of bundles → 66% reduction in CLABSI incidence → principle applicable to VAP bundles + Chastre 2003, JAMA (RCT): 8 days vs. 15 days of VAP treatment → identical mortality rates + 8 days = standard duration + ATS/IDSA 2016 (Kalil, Clinical Infectious Diseases): HAP/VAP guidelines → diagnosis + treatment → de-escalation + duration 7–8 days + CDC/NHSN 2023: updated definitions of healthcare-associated infections (HAIs) → VAP + CLABSI + CAUTI + ICS 2017 + INSPQ Quebec: VAP prevention protocols in intensive care + mandatory reporting of HAIs in Quebec healthcare facilities (MSSS)
Central Line-Associated Bloodstream Infections (CLABSI) and Catheter-Associated Urinary Tract Infections (CAUTI)
CVC bundle, aseptic insertion, chlorhexidine, early catheter removal, CLABSI prevention, antibiotic therapy, CVC duration, DTP: infection vs. contamination
CLABSI : Prevention and Treatment: Central Line Insertion Bundle (IHI): rigorous hand hygiene + skin disinfection with 2 % alcoholic chlorhexidine (superior to povidone-iodine) → Mimoz 2015, Lancet (RCT): 2 % alcohol-based chlorhexidine vs. alcohol-based povidone-iodine → reduction in CLABSIs and colonization → chlorhexidine = standard + maximum sterile barriers (scrub gown + gloves + mask + large sterile drape) + subclavian or internal jugular access preferred over femoral access (less contamination) + remove the catheter as soon as it is no longer essential + chlorhexidine-impregnated sutures (Biopatch) + clear dressings + catheter care: disinfection of valves before each manipulation + antiseptic caps (Curos) → Pronovost 2006, NEJM (Keystone Michigan): CVC bundle → 66% reduction in % CLABSI (from 2.7 to 0 episodes per 1,000 catheter-days in certain units) → seminal publication + CLABSI diagnosis: sepsis + indwelling catheter + positive blood cultures of unknown origin → DTP (Differential Time to Positivity): if a blood culture from the CVC turns positive ≥2 hours before the peripheral blood culture → catheter-related infection + Blot 2004, Lancet ID: DTP > 2 h → sensitivity 89% % + specificity 87% % → CLABSI treatment: remove or change the CVC → follow-up blood cultures → depending on the pathogen: SCN on an uncomplicated, in-place CVC → IV vancomycin × 14 days + catheter removal recommended → S. aureus on a CVC: remove the CVC + vancomycin (MRSA) or cloxacillin (MSA) × 14 days (uncomplicated bacteremia) → ETT/ETO to rule out endocarditis + Candida on CVC: remove the CVC + IV echinocandin × 14 days after the last negative blood culture; CAUTI, prevention and treatment: primary preventive measure: avoid unnecessary bladder catheterization + remove the urinary catheter as soon as it is no longer essential → Gould 2010, Infection Control and Hospital Epidemiology (CDC HICPAC guidelines): CAUTI recommendations → strict indications for catheterization + removal reminder systems → antimicrobial-coated catheters (silver + antibiotic): mixed results in recent studies → Cochrane 2013: inconsistent efficacy → no universal recommendation + meatal hygiene + sterile closed-system catheterization + never break the circuit → CAUTI diagnosis: if catheter is in place → bacteriuria ≥10³ CFU/mL + symptoms → treatment: catheter removal or replacement + antibiotic therapy guided by antibiotic susceptibility testing for 7 days → asymptomatic catheter-associated bacteriuria → DO NOT TREAT (Nicolle 2019, IDSA CIDP) except prior to a urological procedure + clean intermittent catheterization (CIC): preferable to indwelling catheterization in cases of chronic retention Pronovost 2006 : NEJM (Keystone, Michigan): CVC bundle → 66% reduction in CLABSI → seminal publication + Mimoz 2015, Lancet (RCT): 2% alcohol-based chlorhexidine vs. povidone-iodine → chlorhexidine superior → new standard + Blot 2004, Lancet ID: DTP >2h → catheter-related infection → sens. 89 % + spec. 87 % + IDSA 2009 (Mermel : Clinical Infectious Diseases): CLABSI guidelines → treatment based on pathogen + duration + catheter removal + Gould 2010, ICHE (CDC HICPAC CAUTI guidelines): strict indications + early removal → recommendations + Nicolle 2019, IDSA CID: BA on catheter → DO NOT TREAT + CDC NHSN 2023: updated definitions for CLABSI and CAUTI + INSPQ Quebec: mandatory surveillance of CLABSI and CAUTI → MSSS reporting → Quebec Intensive Care Safety Program
Surgical Site Infections (SSI), MRSA, and Antimicrobial Stewardship Programs
Surgical prophylaxis, cefazolin : MRSA, preoperative decolonization, ISO classification, rational antibiotic therapy, rational use of antibiotics, audit, de-escalation
Surgical Site Infections (SSIs) : Prevention and Classification: Classification of SSIs (CDC): Superficial SIS (skin + subcutaneous tissue) + deep SIS (fascia + muscles) + organ/space SIS (cavity + prosthesis) → risk factors for SIS: duration of surgery + colorectal surgery + contamination of the surgical field + obesity + diabetes + smoking + corticosteroids + MRSA carriage + inadequate surgical antibiotic prophylaxis; surgical antibiotic prophylaxis: cefazolin 2 g IV (3 g if >120 kg) within 60 minutes before incision → booster dose if surgery >3 h or >1,500 mL of blood loss → algorithm: Bratzler 2013 : American Journal of Health-System Pharmacy (ASHP/IDSA/SIS/SHEA guidelines): cefazolin = antibiotic of choice for most clean-contaminated surgeries → clindamycin + gentamicin if beta-lactam allergy + vancomycin if preoperative MRSA carrier → no prolonged prophylaxis >24 hours (except for cardiac and orthopedic cases) → prevention of ISO through preoperative decolonization: screening for nasal MRSA carriage before high-risk elective surgery (cardiac, orthopedic, or prosthetic) → if MRSA is present: nasal mupirocin 2 % × 5 days + chlorhexidine rinses × 5 days → Bode 2010, NEJM (RCT): preoperative MRSA decolonization → 58% reduction in S. aureus-related surgical site infections → maintenance of intraoperative blood glucose <11 mmol/L + normothermia + adequate oxygenation + normovolemia → reduction in surgical site infections; MRSA, hospital control measures: active screening of nasal carriers upon admission to certain units (intensive care + orthopedics) → nasal swab + perineal/groin swab → contact precautions if carrier: private room + apron + gloves → decolonization if elective surgery is planned + enhanced surface cleaning and disinfection + Edgeworth 2017, Lancet: universal MRSA screening in the ICU → 50% reduction in MRSA % + Huang 2013, NEJM (REDUCE MRSA RCT): universal decolonization in the ICU (nasal mupirocin + chlorhexidine baths) vs. targeted screening → 44% reduction in MRSA infections → 37% reduction in all infections in the ICU → major finding → universal decolonization in the ICU is feasible; Antimicrobial Stewardship Program (ASP): objectives: to optimize clinical outcomes by using appropriate antibiotics + reduce resistance + reduce adverse effects + reduce costs → components: prospective audit + feedback to prescribers + list of antibiotics requiring prior authorization + de-escalation timeframe (48–72 hours after microbiological results) + standardized treatment duration based on diagnosis → biomarkers guiding treatment duration (procalcitonin → Schuetz 2012, Cochrane: procalcitonin-guided → reduction in antibiotic treatment duration without increased mortality + benefits for respiratory infections ++ ) + education for prescribers + Barlam 2016, Clinical Infectious Diseases (IDSA/SHEA): guidelines for healthcare facilities → multidisciplinary program → infectious disease specialist + pharmacist + microbiologist + Canadian data: CNISP (Canadian Nosocomial Infection Surveillance Program : PHAC): national surveillance of MRBs and HAIs + INSPQ Quebec: annual provincial report on HAIs + publication of indicators by facility Bratzler 2013 : American Journal of Health-System Pharmacy (ASHP/IDSA/SIS/SHEA): surgical prophylaxis → cefazolin = standard + duration <24 hours + Bode 2010 : NEJM (RCT): preoperative MRSA decolonization → −58 % ISO for S. aureus + Huang 2013 : NEJM (REDUCE MRSA RCT): universal decolonization in the ICU → −44 % MRSA infections → −37 % all infections → Edgeworth 2017, Lancet: universal MRSA screening in the ICU → −50 % MRSA + Schuetz 2012, Cochrane: procalcitonin-guided → reduced duration of antibiotic therapy without increased mortality + Barlam 2016, CID (IDSA/SHEA ASP guidelines): ASP program → multidisciplinary + audit + de-escalation + INSPQ Quebec + MSSS 2023: HAI assessment + mandatory reporting + CNISP PHAC: national surveillance of AMR + HAI in Canada + CDC 2020: Core Elements of Hospital Antibiotic Stewardship Programs
ℹ️ Handwashing with soap and water is MANDATORY (not hand sanitizer) when caring for patients with Clostridioides difficile, C. difficile spores are resistant to alcohol: The prevention of healthcare-associated infections relies on three inseparable pillars: hand hygiene (alcohol-based hand rub for most situations + soap and water for C. difficile and visibly soiled hands), structured care bundles for each type of HAI, and stewardship programs to limit the emergence of multidrug-resistant bacteria. Reporting HAIs to the MSSS is mandatory in Quebec for all healthcare facilities.
Situations requiring urgent care

Patient admitted to the hospital with profuse diarrhea (>3 bowel movements/24 hours) + abdominal pain + fever + massive leukocytosis (>30 × 10⁹/L) + elevated creatinine following recent antibiotic therapy Severe or fulminant ICD → isolation in single room + contact precautions + hand washing with soap and water + GDH + EIA toxins + PCR on stool → if severity criteria met → oral vancomycin 500 mg × 4/day + abdominal CT scan → if megacolon or perforation → emergency surgery.

A patient in the ICU on mechanical ventilation who developed a fever, purulent tracheal aspirate, and new infiltrates on a chest X-ray after 5 days of mechanical ventilation → Late VAP → cultures (BAL + tracheal aspiration + blood cultures) → empirical broad-spectrum antibiotic therapy covering MRSA (piperacillin-tazobactam + vancomycin) → de-escalation at 48–72h according to antibiogram → reinforced VAP bundle.

Sudden fever + chills + hypotension within hours of manipulation of a central venous catheter → Probable bacteremia on central venous catheter → Blood cultures x2 (on CVC + peripheral vein) → DTP → if MRSA or S. aureus → removal of CVC + IV vancomycin + TTE/TEE → if uncomplicated SCN on CVC and difficult to remove → treatment without removal can be discussed with the infectious disease specialist → monitoring of control blood cultures.

A patient colonized with a carbapenemase-producing Enterobacteriaceae (CPE) identified upon admission or during hospitalization → Enhanced contact precautions + private room + disinfection and sanitization of surfaces with a virucidal product + reporting to INSPQ and MSSS (mandatory declaration) + contact tracing + no treatment for asymptomatic colonization → treatment for invasive infection: ceftazidime-avibactam +/- meropenem-vaborbactam depending on the resistance mechanism.

Consult at Clinique Omicron

À Clinique Omicron, une consultation médicale permet d'évaluer vos symptômes, de demander les analyses microbiologiques après une hospitalisation et d'assurer le suivi d'une infection associée aux soins de santé. Pour les cas complexes, une orientation vers un infectiologue peut être faite. Consultations en clinique ou en téléconsultation. Au moment de réserver, indiquez le motif de votre consultation. Pour faire une demande de rendez-vous, Choose your online service.

The content on this page is provided for informational purposes only and is not a substitute for the advice of a physician specializing in infectious diseases or infection prevention and control. Protocols for preventing healthcare-associated infections vary by facility and must be adapted to local epidemiological data.

Omicron Clinic

Need to consult a doctor?

In-person or via telemedicine, anywhere in Quebec.

We accept insurance. Telemedicine consultations available 7 days a week. No family doctor required.